On November 13, GeneDx Holdings fell 5.28% in Regular Trading, trading at $49.525 per share, with turnover of $10.245 million.
The move appears tied to continued post-earnings digestion of the company’s cautious forward outlook, alongside analyst target price reductions despite some maintained buy ratings.
GeneDx Holdings reported third-quarter adjusted EPS of $0.28 on revenue of $123.1 million, ahead of consensus expectations of $0.07 and $122.9 million, respectively. However, the company guided fourth-quarter revenue to $135.0 million versus expectations of $142.6 million and reiterated full-year revenue of $475 million to $490 million, compared with consensus of $482.3 million. After the report, Piper Sandler maintained a buy rating with a $95 target, while BTIG cut its target to $85 from $90 and Jefferies reduced its target to $80 from $100, reflecting a more cautious view on near-term growth cadence.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments